5.54
+0.26(+4.92%)
Currency In USD
| Previous Close | 5.28 |
| Open | 5.3 |
| Day High | 5.6 |
| Day Low | 5.26 |
| 52-Week High | 5.86 |
| 52-Week Low | 1.33 |
| Volume | 1.46M |
| Average Volume | 1.86M |
| Market Cap | 766.11M |
| PE | -12.31 |
| EPS | -0.45 |
| Moving Average 50 Days | 4.29 |
| Moving Average 200 Days | 3 |
| Change | 0.26 |
If you invested $1000 in Compass Therapeutics, Inc. (CMPX) since IPO date, it would be worth $651.76 as of December 04, 2025 at a share price of $5.54. Whereas If you bought $1000 worth of Compass Therapeutics, Inc. (CMPX) shares 3 years ago, it would be worth $1,222.96 as of December 04, 2025 at a share price of $5.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Compass Therapeutics to Participate in Upcoming December Investor Events
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire Inc.
Nov 04, 2025 2:00 PM GMT
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed select competitive antibodies in the class, inclu
Compass Therapeutics to Participate in Upcoming November Investor Events
GlobeNewswire Inc.
Nov 03, 2025 1:00 PM GMT
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today